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Background: Ezetimibe's mechanism of action, complementary to that of statins, makes it a
useful therapeutic option in patients intolerant of lipid-lowering drugs or in those not
achieving target lipid levels.
Objectives: To evaluate the efﬁcacy and safety of ezetimibe in a longterm follow-up of lipid clinic
patients with emphasis on motivation for use and the impact on achievement of target lipid levels.
Methods: Two hundred and ninety-ﬁve clinic patients who were prescribed and took eze-
timibe in the 13-month period following the drug's availability in Canada were identiﬁed
from our database. Patients' history and laboratory data were collected before and at ﬁrst
visit after the ezetimibe therapy was started. Paired t-test and chi-square test were used for
statistical comparisons of ezetimibe's effect on lipid parameters and the achievement of
target lipid-levels respectively.
Results: Ezetimibe treatment increased signiﬁcantly the proportion of patients achieving lipid
targets (by 25%forLDL-C and by 21.7% for TC/HDL-C) signiﬁcantly by 18% ( p < 0.001) andTC/HDL-C
by 15% ( p < 0.011). The effect of ezetimibe in combination with other lipid-lowering therapies was
similar; LDL-C decreased by 22% ( p < 0.001) and TC/HDL-C by 15.4% ( p < 0.011). The same lipid-
lowering effect was seen in patients with diabetes. In this subgroup, addition of ezetimibe to
ongoing therapy led to three- and two-fold increase in LDL-C and TC/HDL-C target levels achieve-
ment, respectively. Only 7% of patients discontinued ezetimibe treatment due to side effects.
Conclusion: In patients referred to the lipid clinic (typically because of side effects or failure to
reach targets on other lipid-lowering therapy) treatment with ezetimibe signiﬁcantly in-
creased proportion of those achieving their target lipid levels. This was not accompanied by
signiﬁcant side effects.
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Increased plasma low-density lipoprotein cholesterol (LDL-C)
concentration is a well-established risk factor for cardiovas-
cular disease. Lipid-lowering, particularly with statins, has
been shown to reduce cardiovascular events and prevent
cardiovascular deaths [1]. However, results of a number of
clinical trials highlighted the need for reaching even lower
target levels of LDL-C and this has led expert panels to revise
their recommendations [2–4]. Thus the most recent EAS/ESC
Guidelines for the management of dyslipidaemias lowered the
LDL-C target level to <1.8 mmol/l in the ‘‘very’’ high-risk
category patients [5]. Given that the most aggressive statin
therapy can reduce LDL-C concentrations up to 60% and
considering only 52.5% of CAD patients enrolled into Euro-
aspire III study achieved target LDL-C levels, there evidently is
a need for more powerful hypolipidemic therapies [1,6]. The
ﬁrst selective cholesterol absorption inhibitor, ezetimibe, can
be added when statin monotherapy is insufﬁcient to achieve
the LDL-C target levels or employed as monotherapy in cases
of statin intolerance. Moreover, combination of ezetimibe with
a statin decreases both endogenous (hepatocyte production)
and exogenous (gastrointestinal absorption) sources of cho-
lesterol. This results in an additional decrease of LDL-C levels
of approximately 20% compared to what could be reached on
statin alone [7,8]. Similar LDL-C lowering up to 15% is possible
with ezetimibe as monotherapy. This is of particular impor-
tance in patients with a history of statin intolerance [9].
Although the most pronounced change after ezetimibe
treatment is the decrease of LDL cholesterol, there are other
positive changes such as signiﬁcant decrease of triglycerides
(TG) and small increase in high-density lipoprotein cholesterol
(HDL-C) level [10]. When ezetimibe is added to statin therapy,
the LDL-cholesterol decrease is equal to a three-step titration
of standard statin therapy [11]. Ezetimibe and ﬁbrate combi-
nation has also been proved as effective and safe therapeutic
option in subjects with mixed dyslipidemia [12].
In the paper we summarize our experience with a 13-
month follow-up of patients treated with ezetimibe with focus
on indication for this medication and its effects on lipids.
Methods
The study was designed as a retrospective chart review. Two
thousand six hundred and ninety-eight patients had appoint-
ments at the Lipid Clinic of the St. Paul's Hospital Healthy
Heart Program in the 13-month period of the study. For
inclusion in the study, patients had to be: (1) over age 18 years,
(2) ezetimibe-naïve, (3) prescribed and taken ezetimibe as part
of their treatment at our lipid clinic. Further, a pre-ezetimibe
lipid-panel performed in the 6 weeks prior to the administra-
tion of ezetimibe was required. Alternatively, patients already
taking ezetimibe upon arrival to the clinic were included
provided that lipid values (also taken within 6 weeks prior to
the initial administration of ezetimibe) and medication record
were available from the referring physician. Two hundred and
ninety-nine patients met the inclusion criteria. Exclusion
criteria were: untreated or undertreated hypothyroidism,chronic hepatic or renal disease, chronic alcohol abuse, HIV
infection and pregnancy. Four subjects were excluded leaving
295 subjects in the study. The study was approved by the UBC-
Providence Health Care Research Ethics Board.
Data were collected by two trained individuals under the
supervision of a physician. They included name, sex, age,
presumed lipid diagnosis (using clinical criteria), history of
diabetes, hypertension and cardiovascular disease. Framing-
ham risk category was determined in all subjects at baseline.
Laboratory and medication information was collected on each
patient at baseline (before ezetimibe) and follow-up visits. Lab
data included TC, HDL-C, TG and apolipoprotein B100 (apoB)
levels. LDL-C concentrations were calculated using the
Friedewald equation. Medications recorded included statins,
ﬁbrates, resins, salmon oil, and niacin. All patients were
prescribed ezetimibe 10 mg once daily. Baseline data were
available for the whole cohort (n = 295) and follow-up data
were available from 235 individuals. To examine the data in
the most meaningful way, we focussed our attention to those
patients for whom the prescription of ezetimibe was the only
change in lipid-lowering therapy between the baseline and
follow-up visits (n = 121). In addition ezetimibe's performance
as a monotherapy was evaluated in 37 subjects who were not
on any medications upon arrival and started ezetimibe at our
clinic. We have also assessed the effect of ezetimibe in patients
with type two diabetes mellitus. Twenty-seven patients with
diabetes who did not have additional change in their lipid-
lowering medication during the follow-up, except for ezeti-
mibe, were examined as a subgroup.
The difference between baseline and follow-up lipid and
lipoprotein levels was evaluated using paired two-tail t-test.
The difference in risk targets achievement rate was assessed
using chi-squared test.
Results
Baseline characteristics of the whole patient cohort (n = 295) and
the sub-cohort (n = 121, ezetimibe as the only medication
change) as deﬁned above are shown in Table 1. The table also
shows the rate of achievement of target levels of LDL-C and
targets of TC/HDL-C ratio according to Framingham risk
category. Only a small fraction of patients were achieving their
lipid targets. This was especially the case of high-risk group (4%
and 22% met targets for LDL-C and TC/HDL-C respectively in the
sub-cohort). Comparison of the 121-patient sub-cohort baseline
and follow-up characteristics is shown in Table 2. Addition of
ezetimibe led to a signiﬁcant decrease (p < 0.011) of TC, TG, LDL-
C, TC/HDL-C and apoB. The trend toward increase of HDL-C
concentrations did not reach statistical signiﬁcance. Pairwise
comparison of risk target achievement showed statistically
signiﬁcant improvement after ezetimibe was started. Most
importantly, signiﬁcant improvement was observed in the high-
risk patient category, in which the number of patients achieving
LDL-C and TC/HDL-C targets increased by 25.1% and 21.7%,
respectively (Table 3). In patients in whom ezetimibe was used
as a monotherapy (n = 37) TC, LDL-C, TC/HDL-C and apoB were
also signiﬁcantly reduced (p < 0.001). HDL-C levels rose by 4%
and TG levels decreased by 8%, however, these changes were not
statistically signiﬁcant (p = 0.1). In subjects with type 2 diabetes
Table 1 – Baseline characteristics of the whole cohort (n = 295) and the sub-cohort (n = 121).
Whole cohort % Sub-cohort %
Males 172 58 66 55
Females 123 42 55 45
Age (years, SD) 57.9  11.0 59.6  11.4
Diagnosis FCH 100 34 41 34
heFH 66 22 28 23
PH 119 40 46 38
Other 10 4 6 5
Diabetes mellitus 59 20 27 22
Hypertension 128 43 51 42
Primary prevention 156 53 64 53
Secondary prevention 139 47 57 47
Framingham risk Low 21 7 13 11
Status Medium 79 27 31 26
High 195 66 77 63
TC mmol/l 6.4  1.6 6.5  1.7
HDL-C mmol/l 1.20  0.4 1.3  0.4
TG mmol/l 2.7  2.3 2.7  2.1
TC/HDL-C 5.7  2.4 5.5  2.1
LDL-C mmol/l 4.1  1.4 4.2  1.3
ApoB g/l 1.3  0.3 1.3  0.3
LDL on target 40 14 13 11
TC/HDL on target 76 26 38 31
FCH – familial combined hyperlipidemia, heFH – heterozygous familial hypercholesterolemia, PH – polygenic hypercholesterolemia, TC – total
cholesterol, TG – triglycerides, HDL-C – high-density lipoprotein cholesterol, LDL-C – low-density lipoprotein cholesterol, apoB – apolipoprotein B.
Table 2 – Comparison of the sub-cohort baseline and follow-up characteristics.
n Visit 1 Visit 2 Diff. % p Value
TC 117 mmol/l 6.6  1.7 5.6  1.5 1.0  0.8 15 p < 0.001
HDL-C 116 mmol/l 1.3  0.4 1.3  0.4 0.0  0.2 +2 ns
TG 115 mmol/l 2.7  2.2 2.3  1.7 0.9  0.7 33 p < 0.001
TC/HDL-C 115 5.5  2.1 4.6  1.8 0.3  1.4 6 p = 0.011
LDL-C 101 mmol/l 4.2  1.3 3.3  1.1 0.9  1.0 21 p < 0.001
ApoB 30 g/l 1.3  0.3 1.1  0.2 0.2  0.1 15 p < 0.001
n – number, TC – total cholesterol, TG – triglycerides, HDL-C – high-density lipoprotein cholesterol, LDL-C – low-density lipoprotein cholesterol,
apoB – apolipoprotein B, diff. – difference visit 2  visit 1.
Table 3 – Risk target achievement at baseline and follow-up.
Visit 1 % Visit 2 % Diff. Diff. %
LDL-C At target
Low risk 6/11 55 7/11 63 1 9.1
Mod risk 4/27 15 13/27 48 9 33.3
High risk 3/64 5 19/64 22 16 25
All 13/102a 13 39/102a 38 26 25.1
TC/HDL-C At target
Low risk 8/13 62 9/13 69 1 7.7
Mod risk 13/30 43 22/30 73 9 30.0
High risk 17/72 24 32/72 44 15 20.8
All 38/115b 36 63/115b 55 25 21.7
TC – total cholesterol, TG – triglycerides, HDL-C – high-density lipoprotein cholesterol, LDL-C – low-density lipoprotein cholesterol, diff. –
difference visit 2  visit 1, x2 – chi-square test.
a x2 = 16.1, p < 0.001.
b x2 = 10.17, p = 0.001.
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13%, 16% and 18% respectively (p  0.001) was also documented.
Altogether 26 patients discontinued ezetimibe therapy
during the 13 months period followed: ﬁve due to the cost,
three due to myalgia occurring with the concomitant statintherapy, two for muscle weakness, two for nausea and two due
to constipation. Other miscellaneous causes were present in
single individuals only and were neither serious in nature nor
obviously attributable to ezetimibe. No serious adverse
reaction and no clinically signiﬁcant changes in liver enzymes
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 2 8 – e 1 3 2 e131or creatine kinase levels were noted during the course of the
treatment.
Discussion
In light of results of several recent trials the suggested target
levels of plasma lipids and apoproteins, particularly in high-
risk populations, have been decreasing [5,13,14]. It has been
proven that lowering LDL-C levels below 70 mg/dL brings
additional beneﬁt compared to less aggressive lipid modiﬁca-
tion [2–4]. At the baseline visit only a small proportion of
patients achieved LDL-C and TC/HDL-C targets of the Canadi-
an lipid guidelines [13]. There are several explanations of this
ﬁnding. First, all the patients have been referred to a lipid
clinic, which biases the sample toward those with more
severe, treatment resistant dyslipidemia. There was a rela-
tively large group of patients heterozygous for familial
hypercholesterolemia (22%) or familial combined hyperlipid-
emia (20%) for whom reaching target lipid levels can be more
difﬁcult. Second, we did not include patients who had been
discharged previously from the clinic (typically because their
lipid concentrations were well-controlled). Third, approxi-
mately 50% of the patients had a history of intolerance of a
lipid-lowering medication (mostly statins), which limited the
therapeutic options.
Monotherapy with ezetimibe is a therapeutic option for
patients intolerant of statins (which is the case for the majority
of patients in our cohort who received ezetimibe only).
However, statins remain ﬁrst line therapy in patients with
hypercholesterolemia or high risk for coronary heart disease.
In our monotherapy subgroup we documented statistically
signiﬁcant decrease of TC by 13.5%, LDL-C by 18.7% and apoB
levels by 13.5%, an effect of the same magnitude as seen whenTable 4 – Ezetimibe performance as a monotherapy (n = 37).
Visit 1 Vis
TC mmol/l 7.5  1.5 6.5 
HDL-C mmol/l 1.3  0.3 1.3 
TG mmol/l 2.9  1.7 2.6 
TC/HDL-C 6.0  1.4 5.1 
LDL-C mmol/l 5.0  1.3 4.1 
ApoB g/l 1.4  0.3 1.2 
TC – total cholesterol, HDL-C – high-density lipoprotein cholesterol, TG
apolipoprotein B, diff. – difference visit 2  visit 1.
Table 5 – Ezetimibe performance in a sub-group with diabetes
Visit 1 Visit
TC mmol/l 6.8  2.3 6.0 
HDL-C mmol/l 1.2  0.3 1.3 
TG mmol/l 3.9  2.7 3.7 
TC/HDL-C 5.6  1.6 4.9 
LDL-C mmol/l 3.8  1.1 3.1 
ApoB g/l 1.2  0.2 1.1 
TC – total cholesterol, HDL-C – high-density lipoprotein cholesterol, TG
apolipoprotein B, diff. – difference visit 2  visit 1.ezetimibe is added to a statin. Such an effect is comparable to
lipid-lowering achievable with a starting dose of simvastatin
or atorvastatin and is similar to other reports [15,16].
Our study also included a signiﬁcant proportion of patients
with diabetes in whom the same positive impact on lipid levels
was observed. Improved achievement target lipid levels in this
high-risk group has been demonstrated [17]. As in previous
trials we showed positive impact of ezetimibe on the lipid
parameters typically elevated in type 2 diabetes. Speciﬁcally
we saw a decrease of TG levels by 7% and an increase of HDL-C
by 3% [18]. As the changes are relatively small these results did
not achieve statistical signiﬁcance. However, it is known that
elevation of HDL-C as small as 1 mg/dL translates into 2%
decrease of cardiovascular mortality in men and 3% decrease
in women, highlights the clinical importance of modest
increases in HDL-C associated with ezetimibe treatment
[19]. Most importantly, in patients with diabetes adding
ezetimibe resulted in a three-fold increase in the fraction of
patients meeting LDL and apoB targets and two-fold increase
in that of TC/HDL-C ratio (Tables 4 and 5).
Similar to other studies, the side effects of ezetimibe
treatment are mild and infrequent and resolve after the
therapy is discontinued [20]. In our study price was the most
common reason for stopping the drug (ﬁve patients). Only 21
out of the whole group of 295 patients had other side effects
leading to discontinuation of the ezetimibe treatment. This is
particularly important for the population studied as one half of
the subjects had a history of side effects with their previous
lipid-lowering medication. A relatively common side effect of
hypolipidemic treatment, myalgia, led to discontinuation of
three patients administered statin–ezetimibe combination.
None of them presented signiﬁcant elevation of creatine
kinase levels. We did not note any serious or persistent
adverse reactions in subjects treated with ezetimibe asit 2 Diff. % p Value
 1.1 1.0  0.9 13 p < 0.001
 0.3 0.1  0.2 8 ns
 1.4 0.2  0.9 7 ns
 1.5 0.9  1.0 15 p < 0.011
 1.0 0.9  0.7 18 p < 0.001
 0.3 0.2  0.1 13 p < 0.001
 – triglycerides, LDL-C – low-density lipoprotein cholesterol, apoB –
 (n = 27).
 2 Diff. % p Value
 2.0 0.8  0.9 12 p < 0.001
 0.5 0.0  0.4 3 ns
 2.7 0.3  1.0 7 ns
 1.7 0.7  1.0 13 p < 0.001
 1.1 0.6  1.2 16 p < 0.001
 0.3 0.2  0.8 18 p = 0.001
 – triglycerides, LDL-C – low-density lipoprotein cholesterol, apoB –
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ezetimibe as a relatively new hypolipidemic agent requires
continuing follow-up and evaluation of side effects.
Conclusion
The most frequent reason for initiating ezetimibe was failure
to achieve target lipid levels. One half of the patients did not
achieve targets due to side effects of previous lipid-lowering
therapy. Addition of ezetimibe led to a statistically signiﬁcant
increase in proportion of patients reaching targets. Most
importantly, side effects were unusual and abated upon
discontinuation. Ezetimibe can be safely combined with all
types of hypolipidemic agents used in lipidology practice.
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